Clesrovimab

Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases[1][2][3].

Product Specifications

CAS Number

[2429913-18-6]

Product Name Alternative

MK1654

UNSPSC

12352203

Target

RSV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/clesrovimab.html

Purity

99.89

Solubility

10 mM in DMSO

Smiles

[Clesrovimab]

Molecular Weight

(146.75 kDa)

References & Citations

[1]Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV) . Cytokine Growth Factor Rev. 2022 Dec;68:37-53.|[2]Odumade OA, et al. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection. Clin Infect Dis. 2022 Aug 15;75 (Supplement_1) :S130-S135. |[3]Phuah JY, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother. 2023 Dec 31;169:115851.